Solid-state characterization and dissolution properties of lovastatin hydroxypropyl-β-cyclodextrin inclusion complex

Pharmaceutical Technology

Volumn 31, Issue 2, 2007, Pages 72-82

  Patel, Rakesh P ^a   Patel, Madhabhai M ^a  

^a GANPAT UNIVERSITY   (India)

Author keywords

Hydroxypropyl cyclodextrin; In vitro dissolution studies; Inclusion complexation; Lovastatin

Indexed keywords

COMPLEXATION; DISSOLUTION; INCLUSIONS;

INCLUSION COMPLEXATION; LOVASTATIN;

CYCLODEXTRINS;

2 HYDROXYPROPYL BETA CYCLODEXTRIN; DODECYL SULFATE SODIUM; LACTOSE; MAGNESIUM STEARATE; MEVINOLIN; SILICON DIOXIDE; STARCH; STARCH GLYCOLATE SODIUM;

AQUEOUS SOLUTION; ARTICLE; COMPLEX FORMATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG SOLUBILITY; INFRARED SPECTROSCOPY; SOLID STATE; WETTABILITY; X RAY POWDER DIFFRACTION;

EID: 34748924435     PISSN: 15432521     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. J.S. MacDonald et al., "Preclinical Evaluation of Lovastatin," Am. J. Cardiol. 62 (15), 16J-27J (1998).
2. E.E. Slater and J.S. MacDonald, "Mechanism of Action and Biological Profile of HMG CoA Reductase Inhibitors: A New Therapeutic Alternative," Drugs 36 (Suppl. 3), 72-82 (1998).
3. S.B. Gerald, K.E Dean, and J.K. Micheal, "Lovastatin," in Analytical Profiles of Drug Substances and Excipients, Vol. 21, G.B. Harry, Ed., (Academic Press, Inc., New York, NY, 1992), pp. 277-315.
4. D.O. Thompson, "Cyclodextrins-Enabling Excipients: Their Present and Future Use in Pharmaceuticals," Crit. Rev. Ther. Drug Carrier Syst. 14 (1), 1-104 (1997).
5. C.M. Fernandes, V.M. Teresa, and F.J. Veiga, "Physicochemical Characterization and In Vitro Dissolution Behavior of Nicardipine-Cyclodextrins Inclusion Compounds," Eur. J. Pharm. Sci. 15 (11), 79-88 (2002).
6. M. Kamada et al., "Cyclodextrin Conjugate-Based Controlled Release System: Repeated- and Prolonged-Releases of Ketoprofen after Oral Administration in Rats," J. Control. Release 82 (2-32-3), 407-416 (2002).
7. K. Uekama and M. Otagiri, "Cyclodextrins in Drug Carrier Systems," Crit. Rev. Ther. Drug Carrier Syst. 3 (1), 1-40 (1987).
8. S. Baboota, M. Dhaliwal, and K. Kohli, "Physicochemical Characterization, In Vitro Dissolution Behavior, and Pharmacodynamic Studies of Rofecoxib-cyclodextrin Inclusion Compounds," AAPS PharmSciTech. 6 (1), E83-E90 (2005).
9. G. S. Tirucherai and A. K. Mitra, "Effect of Hydroxypropyl Beta Cyclodextrin Complexation on Aqueous Solubility, Stability, and Corneal Permeation of Acyl Ester Prodrugs of Ganciclovir," AAPS PharmSciTech. 4 (3), E45 (2003).
10. B. N. Nalluri et al., "Physicochemical Characterization and Dissolution Properties of Nimesulide-Cyclodextrin Binary Systems," AAPS PharmSciTechnol. 4 (1), E2 (2003).
11. J. Peeters et al., "Characterization of the Interaction of 2-Hydroxypropyl-Betacyclodextrin with Itraconazole at pH 2, 4, and 7," J. Pharm. Sci. 91 (66), 1414-1422 (2002).
12. F. J. Veiga et al., "Molecular Modeling and 1H-NMR: Ultimate Tools for the Investigation of Tolbutamide: β-Cyclodextrin and Tolbutamide: Hydroxypropyl-β-Cyclodextrin Complexes," Chem. Pharm. Bull (Tokyo). 49 (10), 1251-1256 (2001).
13. J. Szejtli, "Medicinal Applications of Cyclodextrins," Med. Res. Rev. 14 (3), 353-386 (1994).
14. J.W. Moore and H. Flanner, "Mathematical Comparison of Dissolution Profiles," Pharm. Technol. 20 (6), 64-74 (1996).
15. US Food and Drug Administration, Guidance for Industry SUPAC-MR: Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation (FDA, Rockville, MD, 1997).
16. Human Medicines Evaluation Unit, European Agency for the Evaluation of Medicinal Products (EMEA), Notes for Guidance on Quality of Modified-Release Products; A Oral Dosage Forms; B Transdermal Dosage Forms, Section 1 (Quality) (EMEA, London, UK, 1999).
17. C. Reppas and E. Nicolaides, "Analysis of Drug Dissolution Data," in Oral Drug Absorption Prediction and Assessment, J.B. Dressman and H. Lennernäs, Eds. (Marcel Dekker, Inc., New York, NY, 2000), pp. 229-254.
18. M.L. Vueba et al., "Influence of Cellulose Ether Polymers on Ketoprofen Release from Hydrophilic Matrix Tablets," Eur. J. Pharm. and Biopharm. 58 (1), 51-59 (2004).
19. T. Higuchi and K. Connors, "Phase Solubility Techniques," in Advances in Analytical Chemistry and Instrumention, CN. Reilly, Ed. (John Wiley, New York, NY, 1965) 4, 117-212.
20. S. Mattsson and C. Nyström, "The Use of Mercury Porosimetry in Assessing the Effect of Different Binders on the Pore Structure and Bonding Properties of Tablets," Eur. J. Pharm. Biopharm. 52 (2), 237-247 (2001).
21. K. Kawakita, "Compression of Powder," Kagaku. 26, 149-150 (1956).
22. R.L. Carr, "Evaluating Flow Properties of Solids," Chem. Eng. 72 (2), 163-168 (1965).
23. D. Peri et al., "Inclusion Complexes of Tolnaftate with β-Cyclodextrin and Hydroxy-β-Cyclodextrin," Drug Dev. Ind. Pharm. 20 (88), 1401-1410 (1994).
24. J.J.T. Labenderia et al., "Glibornuride-β-Cyclodextrin Inclusion Complexes: Preparation, Structural Characterization, and In Vitro Dissolution Behavior," Eur. J. Pharm. and Biopharm. 39 (6), 255-259 (1993).
25. L. Chengsheng, L. Chenguang, and H.D. Kashappa, "Enhancement of Dissolution Rate of Valdecoxib Using Solid Dispersions with Polyethylene Glycol 4000," Drug Dev. Ind. Pharm. 31 (1), 1-10 (2005).
26. A.R. Hedges. "Industrial Applications of Cyclodextrins " Chemical Reviews 98 (5), 2035-2044 (1998).
27. T. Pralhad and K. Rajendrakumar, "Study of Freeze-Dried Quercetincyclodextrin Binary Systems by DSC, FT-IR, X-ray Diffraction and SEM Analysis," J. Pharm. Biomed. Anal. 34 (2), 333-339 (2004).
28. R.O. Williams, V. Mahaguna, and M. Sriwongjanya, "Characterization of an Inclusion Complex of Cholesterol and Hydroxypropylbcyclodextrin," Eur. J. Pharm. Biopharm. 46 (3), 355-360 (1998).
29. R.K. McMullan et al., "Topography of Cyclodextrin Inclusion Complexes: Part I, Classification of Crystallographic Data of α-Cyclodextrin Inclusion Complexes," Carbohydr. Res. 31 (1), 37-46 (1973).
30. D. Horter and J. B. Dressman, "Influence of Physiochemical Properties on Dissolution of Drugs in the Gastrointestinal Tract," Advanced Drug Delivery Reviews 25 (1), 3-14 (1997).
31. J. P. Skelly et al., "Scale Up of Immediate Release Oral Solid Dosage Forms," J. Parenter. Sci. Technol. 47 (2), 52-56 (1993).
32. E. Galia, J. Horton, and J.B. Dressman, "Albendazole Generics - A Comparative In Vitro Study," Pharm. Res. 16 (12), 1871-1875 (1999).
33. C. Noory et al., "Rethinking the Use of Water as a Dissolution Medium," Dissolution Technol. 6 (4), 6-7 (1999).
34. V. P. Shah et al., "In Vitro Dissolution of Sparingly Water-Soluble Drug Dosage Forms," Int. J. of Pharm. 125 (11), 99-106 (1995).
35. M. Barzegar-Jalali et al., "Enhancement of Dissolution Rate and Anti-Inflammatory Effects of Piroxicam Using Solvent Deposition Technique," Drug Dev. Ind. Pharm. 28 (6), 681-686 (2002).
36. L. Tang, S.U. Khan, and N.A. Muhmmad, "Evaluation and Selection of Bio-relevant Dissolution Media for a Poorly Water Soluble New Chemical Entity," Pharm. Develop. Technol. 6 (44), 531-540 (2001).
37. H. Vromans, A.C. Eisson, and F.L. Coenraad, "Mechanism of Dissolution of Drug-Cyclodextrin Complexes," Drug Dev. Ind. Pharm. 15, 250-255 (1989).
38. M.E. Aulton, "Pharmaceutical Technology," in: Pharmaceutics: The Science of Dosage Form Design (London, UK: Churchill Livingstone, 1988), pp. 600-616.